ZA200505026B - Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders - Google Patents

Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders

Info

Publication number
ZA200505026B
ZA200505026B ZA200505026A ZA200505026A ZA200505026B ZA 200505026 B ZA200505026 B ZA 200505026B ZA 200505026 A ZA200505026 A ZA 200505026A ZA 200505026 A ZA200505026 A ZA 200505026A ZA 200505026 B ZA200505026 B ZA 200505026B
Authority
ZA
South Africa
Prior art keywords
tolterodine
treating urinary
urinary disorders
reduced dose
antimuscarinic agents
Prior art date
Application number
ZA200505026A
Other languages
English (en)
Inventor
Barbara H Korberly
Susan M Danehower
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200505026(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of ZA200505026B publication Critical patent/ZA200505026B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200505026A 2003-01-22 2005-06-21 Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders ZA200505026B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44169003P 2003-01-22 2003-01-22

Publications (1)

Publication Number Publication Date
ZA200505026B true ZA200505026B (en) 2006-07-26

Family

ID=32771960

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200505026A ZA200505026B (en) 2003-01-22 2005-06-21 Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders

Country Status (17)

Country Link
US (2) US20060047007A1 (pt)
EP (1) EP1589958B2 (pt)
JP (1) JP2006515607A (pt)
KR (1) KR20050096147A (pt)
CN (1) CN1741796A (pt)
AT (1) ATE432070T1 (pt)
AU (1) AU2004206110A1 (pt)
BR (1) BRPI0406861A (pt)
CA (1) CA2514022C (pt)
DE (1) DE602004021233D1 (pt)
ES (1) ES2324712T5 (pt)
IL (1) IL169362A0 (pt)
MX (1) MXPA05007767A (pt)
PL (1) PL377995A1 (pt)
TW (1) TW200418447A (pt)
WO (1) WO2004064821A1 (pt)
ZA (1) ZA200505026B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2210605T (pt) * 2003-11-04 2017-04-24 Tcd Royalty Sub Llc Formas de dosagem única diária de tróspio
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
DE602004020337D1 (de) * 2004-08-11 2009-05-14 Boehringer Ingelheim Pharma Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
NZ570492A (en) * 2006-02-13 2011-08-26 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US8377956B2 (en) 2010-03-01 2013-02-19 Xenoport, Inc. Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP2153825A1 (en) * 1998-08-27 2010-02-17 Pfizer Health AB Therapeutic formulation for administering tolterodine with controlled release
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
SI1227806T1 (sl) † 1999-11-11 2005-12-31 Pfizer Health Ab Farmacevtska formulacija, ki vsebuje tolterodin in njena uporaba

Also Published As

Publication number Publication date
CA2514022C (en) 2010-07-13
EP1589958B2 (en) 2012-04-11
TW200418447A (en) 2004-10-01
MXPA05007767A (es) 2006-01-31
PL377995A1 (pl) 2006-02-20
ES2324712T3 (es) 2009-08-13
EP1589958B1 (en) 2009-05-27
ES2324712T5 (es) 2012-06-08
US20070155838A1 (en) 2007-07-05
CA2514022A1 (en) 2004-08-05
WO2004064821A1 (en) 2004-08-05
BRPI0406861A (pt) 2006-01-03
ATE432070T1 (de) 2009-06-15
US20060047007A1 (en) 2006-03-02
JP2006515607A (ja) 2006-06-01
DE602004021233D1 (de) 2009-07-09
AU2004206110A1 (en) 2004-08-05
IL169362A0 (en) 2007-07-04
KR20050096147A (ko) 2005-10-05
CN1741796A (zh) 2006-03-01
EP1589958A1 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
MXPA04003866A (es) Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
IL169362A0 (en) Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2001085154A8 (en) Method of treating immune pathologies with low dose estrogen
EP1600167A3 (en) A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders
WO2002038142A3 (en) Serotonergic compositions and methods for treatment of mild cognitive impairment
PL366430A1 (en) Sustained release formulations of oxymorphone
UY26693A1 (es) Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero
WO2002066427A3 (en) (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
PL1933833T3 (pl) Terapia do leczenia pęcherza nadreaktywnego
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
GB0406384D0 (en) Composition for reducing appetite in mammals comprising proxyanidin
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
WO2002100404A3 (en) Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
HK1024631A1 (en) Use of (+) mefloquine for the treatment of malaria
WO2003049667A3 (en) The method of treating cancer
WO2003015690A3 (en) Method for treating primary insomnia
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
WO2002091990A3 (en) Prevention of addiction in pain management
HUP0101326A2 (hu) Paroxetinkompozíciók és eljárás az előállításukra
IL162391A0 (en) Method of treatment
EP1260221A3 (en) Combination treatment for depression and anxiety
RU2006146071A (ru) Средство для устранения фактора циркуляторной дисфункции
WO2002013825A8 (en) Novel pharmaceutical use of quinnoline derivatives